[Health technology assessment of erlotnib (Tarceva) for palliative treatment of non-small cell lung cancer]
Danish Centre for Evaluation and Health Technology Assessment
Record ID 32006000483
Danish
Original Title:
Medicinsk teknologivurdering af erlotinib (Tarceva) til palliativ behandling af ikke-småcellet lungecancer 24 NOV 2005
Authors' recommendations:
Erlotinib is a new oral drug that increases survival for patients with non-small cell lung cancer where chemotherapy has failed.
Erlotinib has been tested in an international placebo-controlled trial. Treatment effect is on average two to three months longer survival.
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
https://www.sst.dk/da/Udgivelser/2005/Medicinsk-teknologivurdering-af-erlotinib-Tarceva-til-palliativ-behandling-af-ikke-smaacellet-lungec
English language abstract:
There is no English language summary available
Publication Type:
Not Assigned
Country:
Denmark
MeSH Terms
- Erlotinib Hydrochloride
- Palliative Care
- Carcinoma, Non-Small-Cell Lung
- Quinazolines
- Antineoplastic Agents
- Lung Neoplasms
Contact
Organisation Name:
Danish Centre for Evaluation and Health Technology Assessment
Contact Address:
National Board of Health, PO Box 1881, Islands Brygge 67, DK-2300 Copenhagen S, Denmark. Tel: 45 72 22 74 48; Fax: 45 72 22 74 07/67
Contact Name:
dacehta@sst.dk
Contact Email:
dacehta@sst.dk
Copyright:
Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.